From experimental research to clinical trial in the treatment of complication of radiotherapy by stem cells

A Chapel1, A Semont1, C. Linard1, N. Mathieu1, C Demarquay1, C Squiban1, J Voswinkel2, H Rouard3, JJ Lataillade5, C. Martinaud5, M Benderitter1, NC Gorin2, JM Simon4 and M Mothy2

1 Radiological Protection and Human Health Division, Institute of Radiological Protection and Nuclear Safety, Fontenay-aux-Roses, France, 2 Department of Hematology, Saint Antoine Hospital APHP and UPMC University, UMRS 938, Paris, France; 3 Assistance Publique-Hôpitaux de Paris, EFS Ile de France, Banque des Tissus, Creteil, France. 4 Department of Radiation Oncology, Pitie-Salpetriere University Hospital, Paris, France; 5 Blood Transfusion Center of Army, Percy Military Hospital, Clamart, France

### Abstract

**Statement of the problem**: The late adverse effects of pelvic radiotherapy concern 5 to 10% of patients, which could be life threatening. However, a clear medical consensus concerning the clinical management of such healthy tissue sequelae does not exist. Our group has demonstrated in preclinical animal models that systemic mesenchymal stromal stem cells (MSCs) injection is a promising approach for the medical management of gastrointestinal disorder after irradiation.

**Methodology & theoretical orientation:** In a phase 1 clinical trial, we have shown that the clinical status of four first patients suffering from severe pelvic side effects (Epinal accident) was improved following MSC injection (figure). Two patients revealed a substantiated clinical response for pain and hemorrhage after MSC therapy. The frequency of painful diarrhea diminished from 6/d to 3/d after the first and 2/d after the 2nd MSC injection in one patient.

**Findings:** A beginning fistulization process could be stopped in one patient resulting in a stable remission for more than 3 years of follow-up. A modulation of the lymphocyte subsets towards a regulatory pattern and diminution of activated T cells accompanies the clinical response. MSC therapy was effective on pain, diarrhea, hemorrhage, inflammation, fibrosis and limited fistulization. No toxicity was observed.

We are now starting a clinical research protocol for patients with post-radiation abdominal and pelvic complications who have not seen their symptoms improve after conventional treatments (NCT02814864, Trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy (PRISME). It involves the participation of 6 radiotherapy services for the recruitment of 12 patients. They will all be treated and followed up in the hematology department of Saint Antoine Hospital. The cells will be prepared in two production centers (EFS Mondor and CTSA). Treatment is a suspension of allogeneic MSCs. Eligible patients must have a grade greater than 2 for rectoragy or hematuria at inclusion and absence of active cancer. Each patient receives 3 injections of MSCs at 7-day intervals. Patients will be followed up over a 12-month period. The main objective is a decrease of one grade on the LENT SOMA scale for rectorrhagia or hematuria. The secondary objective is to reduce the frequency of diarrhea, analgesic consumption, pain and improved quality of life.

**Conclusion:** At the end of this period, if the efficacy of the treatment is proven, a phase III trial including a larger number of patients over a longer period will be used to confirm the therapeutic properties of this treatment.

**References**

1. Chapel A. Cells. 2021; 10(4):760.
2. Usunier B, Brossard C, L'Homme B, Linard C, Benderitter M, Milliat F, Chapel A. Int J Mol Sci. 2021 Feb 11;22(4):1790.
3. François S, Usunier B, Forgue-Lafitte ME, L'Homme B, Benderitter M, Douay L, Gorin NC, Larsen AK, Chapel A. Stem Cells Transl Med.2019; 8(3):285-300.
4. François S, Eder VV, Belmokhtar K, Machet MC, Douay L, Gorin NC, Benderitter M, Chapel A. Sci Rep. 2017 Jun 27;7(1):4272.
5. Usunier B, Benderitter M, Tamarat R, Chapel A. 2014; Stem Cells Int. 340257.
6. Larbi A, Mitjavila-Garcia MT, Flamant S, Valogne Y, Clay D, Usunier B, l'Homme B, Féraud O, Casal I, Gobbo E, Divers D, Chapel A, Turhan AG, Bennaceur-Griscelli A, Haddad R. 2014, Stem Cells Dev. 29.
7. François S, Usunier B, Douay L, Benderitter M, Chapel A. Stem Cells Int. 2014; 2014: 939275.
8. Fouillard L, Francois S, Bouchet S, Bensidhoum M, Elm'selmi A, Chapel A. 2014; Curr Pharm Biotechnol. 14, 842-8.
9. Benderitter M, Caviggioli F, Chapel A, Coppes RP, Guha C, Klinger M, Malard O, Stewart F, Tamarat R, Luijk PV, Limoli CL. 2014; Antioxid Redox Signal. 21, 338-55.
10. Voswinkel J, Francois S, Gorin NC, Chapel A. Immunol Res. 2013 Jul;56(2-3):241-8
11. Larbi A, Gombert JM, Auvray C, l'Homme B, Magniez A, Féraud O, Coulombel L, Chapel A, Mitjavila-Garcia MT, Turhan AG, Haddad R, Bennaceur-Griscelli A. PLoS One. 2012;7(6):e39514.
12. Kobari L, Yates F, Oudrhiri N, Francina A, Kiger L, Mazurier C, Rouzbeh S, El-Nemer W, Hebert N, Giarratana MC, François S, Chapel A, Lapillonne H, Luton D, Bennaceur-Griscelli A, Douay L. Haematologica. 2012 Dec;97(12):1795-803.

**Biography**

For 30 years, he has been developing gene and cell therapy using non-human primates, immune-tolerant mice and rats to protect against the side effects of radiation. He collaborates with clinicians to develop strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after totl body irradiation. He is scientific investigator of Clinical phase II trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy (NCT02814864Hirsch Index 31)